Barrett’s Esophagus and Sodium Alginate: What Does the Research Show?

Barrett’s esophagus is a precancerous change in the lining of the esophagus, almost always driven by long-standing acid reflux (GERD). Chronic acid exposure causes the delicate esophageal cells to transform into intestinal-type cells that can better survive the acid, but this adaptation carries a small, lifelong risk of esophageal cancer. Management is directed by your gastroenterologist and centers on controlling reflux, medication when appropriate, and endoscopic surveillance. In this article, we explain what Barrett’s esophagus is, how it is diagnosed and treated under current guidelines, and what the research on sodium alginate, a raft-forming reflux ingredient, does and does not show for people with Barrett’s.

Barrett’s Esophagus: Key Facts

• What it is: A change in the esophageal lining (intestinal-type cells) caused by chronic acid reflux, considered a precancerous condition.
• Why it matters: Around 5% to 13% of people with GERD develop Barrett’s, and it raises the long-term risk of esophageal cancer, though only about 0.1% to 0.3% of patients progress to cancer each year.
• How Barrett’s is managed: Medical management generally includes control of gastroesophageal reflux, PPI therapy when appropriate, lifestyle measures, and endoscopic surveillance based on the patient’s risk profile.
• Where alginate fits: Alginate therapy has been studied separately as a mechanical approach to reducing reflux, but it has not been shown to prevent progression of Barrett’s esophagus.

At Nutritist, our mission is simple: bring evidence-based supplements to the people who need them most. We make Refluxter, an alginate-based reflux supplement formulated by an M.D. who personally lives with GERD, and we discuss how it is formulated near the end of this article. Let’s start with the medical facts: what Barrett’s esophagus is, how it is diagnosed and treated, and where reflux control fits in.

What Is Barrett’s Esophagus?

Barrett’s esophagus describes the transformation of your esophageal lining into a type of cell normally found in your intestines. In plain terms, a section of your esophagus (your food pipe) starts to grow cells that belong in the gut instead.

This happens because of chronic exposure to stomach acid. Normally, the lower esophageal sphincter (LES) seals off the food pipe from the stomach. When that sphincter loosens, the relatively sensitive cells of the esophagus are bathed in the low pH of stomach acid.

Through a process called homeostasis, the body’s drive to find balance, the esophageal cells adapt by transforming into a sturdier cell type that can survive this harsh environment. The trade-off is that, left untreated, Barrett’s esophagus can progress toward esophageal cancer in a small minority of patients.

What Causes Barrett’s Esophagus?

Scientists haven’t pinned down a single exact cause, but the vast majority of patients have gastroesophageal reflux disease (GERD). When the LES muscles relax inappropriately, stomach contents regurgitate up into the esophagus. People with acid reflux are roughly 5 times more likely to develop Barrett’s, although some patients develop it without ever having classic GERD.

According to reports, about 5% to 13% of people with GERD will develop Barrett’s esophagus. It is roughly twice as common in men as in women, and most cases are discovered at age 55 or older. Importantly, having Barrett’s does not mean cancer is inevitable; only about 0.1% to 0.3% of patients develop esophageal cancer each year, and guideline-directed surveillance is designed to catch any early changes when they are most treatable.

Risk Factors for Barrett’s Esophagus

Having GERD for more than a decade raises the risk substantially, though it’s all relative, since only 5% to 10% of GERD cases ever convert to Barrett’s. Aside from GERD, common risk factors include:

• Gender: Males are more likely to develop Barrett’s.
• Race: Caucasians are at higher risk.
• Age: Most diagnoses occur after age 55.
• History of gastric infection: Particularly gastritis caused by H. pylori.
• Weight: Overweight and obese individuals are at higher risk.
• Smoking.

The same factors that worsen GERD can also aggravate reflux in people with Barrett’s esophagus, including smoking, alcohol, frequent NSAID use, large meal portions, diets high in saturated fat, spicy foods, and lying down soon after eating. Many people with GERD also experience laryngopharyngeal reflux (LPR), or silent reflux. We cover that in detail in our article on sodium alginate for LPR.

Signs and Symptoms of Barrett’s Esophagus

Barrett’s esophagus itself has no specific symptoms. Because most patients also have GERD, they typically report heartburn and the usual reflux symptoms rather than anything unique to Barrett’s. That’s exactly why surveillance matters: the condition is often silent.

That said, call your doctor immediately if you develop any of these warning signs:

• Severe chest pain.
• Dysphagia (difficulty swallowing).
• Hematemesis (vomiting blood).
• Melena (black or tarry stools).

Can Barrett’s Esophagus Turn Into Cancer?

Barrett’s esophagus raises the chance of esophageal cancer, but that cancer remains relatively rare; reports suggest roughly 10 out of 1,000 people with Barrett’s will develop cancer over the course of 10 years. If you have Barrett’s, your doctor will review your history and schedule regular checkups to watch for early changes, often taking biopsies to examine the tissue for precancerous cells. When precancerous cells are present, the condition is called dysplasia.

Early detection is crucial to a good outcome, which is why regular surveillance is indispensable for anyone with Barrett’s esophagus (Shaheen et al.).

How Barrett’s Esophagus Is Diagnosed

Most cases are diagnosed around age 55. When you see your doctor with heartburn, they’ll take a history, perform a physical exam, and usually recommend an endoscopy. During an endoscopy, a thin, flexible tube with a camera and light is passed down to inspect the lower esophagus for tissue changes. If Barrett’s is suspected, the doctor takes a tissue sample, and a pathologist examines it under the microscope for dysplasia.

Follow-up endoscopies are then scheduled on a surveillance timeline tailored to your risk profile. Under the American College of Gastroenterology’s updated guideline, surveillance intervals for nondysplastic Barrett’s are stratified in part by the length of the Barrett’s segment (Shaheen et al.):

• For segments shorter than 3 cm with no dysplasia, surveillance endoscopy is generally recommended about every 5 years after an adequate initial examination.
• For segments 3 cm or longer with no dysplasia, surveillance is generally recommended about every 3 years.
• If dysplasia is found, surveillance and treatment are intensified, as described in the next section.

An automatic repeat endoscopy 12 months after an adequate initial examination is no longer recommended for nondysplastic Barrett’s. Your gastroenterologist may adjust these intervals based on your individual findings, so follow the schedule your own physician recommends.

Treatment Options for Barrett’s Esophagus

Treatment depends on whether dysplasia is present and, if so, its grade. Current recommendations come from the ACG’s 2022 guideline and the American Gastroenterological Association’s 2024 guideline on endoscopic eradication therapy (EET).

If you have Barrett’s esophagus, do not discontinue a PPI or other treatment prescribed by your gastroenterologist in favor of an alginate product. Alginate therapy has not been established as a substitute for guideline-directed Barrett’s treatment or surveillance. The ACG suggests at least once-daily PPI therapy for Barrett’s patients without contraindications, and the AGA’s 2025 surveillance guideline likewise conditionally recommends daily PPI therapy to help prevent progression.

Nondysplastic Barrett’s Esophagus

When no dysplasia is present, management centers on reflux control (typically once-daily PPI therapy), lifestyle measures, and surveillance endoscopy on the intervals described above. The AGA suggests against routine endoscopic eradication therapy for nondysplastic Barrett’s.

Low-Grade Dysplasia

Low-grade dysplasia means dysplasia is present, but the cellular changes are less advanced than in high-grade dysplasia. (If no dysplasia is present, the condition is called nondysplastic Barrett’s, not low-grade dysplasia.) After the diagnosis is confirmed by an expert pathologist, the 2024 AGA guideline suggests endoscopic eradication therapy over surveillance for confirmed low-grade dysplasia, while noting that continued close surveillance (typically every 6 to 12 months) remains a reasonable choice for patients who weigh the procedural risks more heavily. This is a shared decision to make with your gastroenterologist.

High-Grade Dysplasia

High-grade dysplasia involves more advanced precancerous changes and calls for definitive treatment. The 2024 AGA guideline recommends endoscopic eradication therapy for high-grade dysplasia. EET techniques include:

• Endoscopic resection: Removal of visible abnormal tissue through the endoscope.
• Radiofrequency ablation: An endoscope delivers heat to destroy the abnormal cells.
• Cryotherapy: An endoscope releases cold gas to freeze the dysplastic cells; repeated freeze-thaw cycles kill the abnormal tissue.

Esophagectomy (surgical removal of part of the esophagus) is now reserved for select cases, since endoscopic therapy is effective for most patients with dysplasia or very early cancer.

Anti-Reflux Procedures

Separately from dysplasia treatment, patients whose GERD symptoms don’t improve with medication may discuss anti-reflux procedures with a surgeon:

• Nissen Fundoplication: Tightens the LES by wrapping the top of the stomach around the outside of the sphincter to increase its tone.
• LINX: A ring of magnetic beads placed around the esophagus; the beads attract one another to keep stomach contents from leaking upward.
• TIF Procedure: Transoral Incisionless Fundoplication, an incision-free technique in which a device passed through the mouth partially wraps the esophagus 270 to 300 degrees, with shorter recovery than traditional Nissen fundoplication.

These procedures address reflux symptoms. For preventing progression of Barrett’s itself, the 2025 AGA guideline conditionally favors daily PPI therapy over anti-reflux surgery.

Understanding GERD: The Root Cause

To understand Barrett’s, you have to understand reflux. When you eat, food travels from the mouth through the esophagus to the stomach. To keep acid from traveling back up, the lower esophagus has a thick muscular ring, the LES, that contracts to block backflow. The system isn’t perfect: when the LES opens when it should stay closed, acid escapes upward, producing GERD.

For most people GERD is benign, but if you have symptoms at least twice a week, you may be dealing with the disease rather than occasional heartburn. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GERD affects roughly 20% of Americans, and left untreated, it can precipitate serious complications, including Barrett’s esophagus.

Managing GERD

Controlling GERD calls for a holistic approach across diet, exercise, medication, and lifestyle. Eat more fiber, cut back on reflux triggers like chocolate and alcohol, exercise to support digestion, and elevate your upper body when you sleep. Many patients also use one of these medication classes:

• Antacids.
• H2-receptor blockers.
• Proton pump inhibitors (PPIs).

PPIs remain the standard medical therapy for GERD and for Barrett’s patients specifically. Even so, some people continue to experience breakthrough reflux episodes, particularly after meals and at night. That residual reflux is where raft-forming alginates have been studied as an additional, mechanical approach. If medications don’t bring relief, it may also be worth talking to a physician about whether you’re a candidate for the anti-reflux procedures described above.

The Under-Discussed Role of Alginate Rafts

Sodium alginate therapy is a rapidly growing area of interest for reflux control. Raft-forming alginate creates a low-density, viscous gel the moment it meets stomach acid. That gel-like raft floats on top of the “acid pocket” that forms after a meal, acting as a physical lid that keeps acidic contents from washing back into the esophagus (Rohof et al.).

The best part is its near-instant action: take alginate with bicarbonate and the raft forms within seconds. It’s important to understand what alginate does and doesn’t do: it’s preventive, not a rescue antacid. Taken consistently, it helps prevent future reflux episodes, but it can’t neutralize acid that is already up in the esophagus.

The research on reflux is encouraging. In one study, an alginate-antacid preparation formed a raft just beneath the LES that blocked the post-meal reflux a non-raft-forming antacid failed to stop. In another study of patients with symptomatic GERD and hiatal hernia, the group taking an alginate-antacid had significantly fewer reflux episodes, and the time before reflux occurred after a meal stretched to about one hour, versus just 14 minutes for the non-raft antacid group (Rohof et al.). In short, alginate-antacid preparations have been shown to help reduce both the frequency and the onset of GERD symptoms.

What Does Research Say About Alginate and Barrett’s Esophagus?

Most clinical research on alginate therapy has focused on gastroesophageal reflux disease rather than Barrett’s esophagus itself. However, a 2023 laboratory study provides an interesting look at how alginate may interact with esophageal cells exposed to pepsin, one of the components of gastric reflux (Samuels et al.).

Researchers used BAR-T cells, a human cell line derived from Barrett’s esophageal epithelium, and exposed them to acidic pepsin to model some of the cellular injury associated with reflux. The researchers found that pepsin exposure damaged proteins involved in maintaining the integrity of the epithelial barrier, including E-cadherin.

Pretreatment with alginate formulations reduced several of these effects. Notably, one of the formulations studied contained sodium alginate, sodium bicarbonate, and calcium carbonate, three ingredients commonly used in raft-forming alginate preparations.

These findings are intriguing because refluxate can contain more than acid. Pepsin and other gastric contents may also reach the esophagus, including during weakly acidic reflux.

However, there is an important limitation: this was a laboratory study using cultured cells, not a clinical trial in people with Barrett’s esophagus. It therefore does not demonstrate that taking alginate can reverse Barrett’s esophagus, prevent dysplasia, or reduce the risk of esophageal cancer.

There is also one small human study. In a pilot study at the Medical University of South Carolina (NCT03193216), 24 patients with dysplastic Barrett’s esophagus undergoing endoscopic eradication therapy added a European liquid alginate (10 mL four times daily, after meals and at bedtime) to standard twice-daily PPI therapy, and their outcomes were compared with a matched historical group of 21 patients treated with PPI therapy alone. The rationale was that even on strong acid suppression, some patients continue to reflux pepsin, bile, and other gastric contents, and a physical alginate barrier might reduce that exposure while the treated esophagus heals. In results posted to the trial registry, the alginate group showed numerically higher eradication rates and required fewer treatment sessions on average, with no serious adverse events reported.

These findings are directionally interesting, but they are far from definitive. The study was small, open-label, and single-center; it used historical rather than randomized controls; only 14 of the 24 enrolled patients completed it; no statistical significance testing was reported; and the results have not, to our knowledge, been published in a peer-reviewed journal. The product studied was also a pharmaceutical alginate preparation, not a dietary supplement. A pilot of this size cannot establish that alginate improves eradication of Barrett’s esophagus, and it does not change the guidance above: alginate is not a treatment for Barrett’s esophagus and is not a substitute for PPI therapy, endoscopic treatment, or surveillance.

For people diagnosed with Barrett’s esophagus, alginate therapy should not replace physician-directed treatment, proton pump inhibitor therapy when prescribed, or recommended endoscopic surveillance. Instead, these studies add to the scientific understanding of how alginate may interact with refluxed gastric contents and the esophageal epithelial barrier.

How Refluxter Is Formulated

So how do you evaluate an alginate preparation? Because alginate products are sold as supplements, manufacturers aren’t told exactly how to formulate them, so formulations vary widely. Some include ingredients you may prefer to avoid, like aluminum and parabens, or sweeteners such as dextrose, stevia, or xylitol that can cause bloating and gastric distress in some people.

Refluxter by Nutritist was formulated by an M.D. using the same classes of ingredients studied in the published raft-forming alginate research cited in this article: sodium alginate together with bicarbonate and carbonate. To be clear, the clinical studies cited here were conducted on other formulations, and Refluxter itself has not been the subject of clinical trials. For comparison, one leading competitor uses calcium pantothenate, a form of vitamin B5 with no established role in raft formation, rather than calcium carbonate.

On dose: by FDA labeling rules, ingredients must be listed in descending order of weight. Sodium alginate is the first ingredient in Refluxter’s alginate complex, which weighs 1,470 mg per serving, with 1,000+ mg of that being sodium alginate. Among the competitor gels we have compared, one competitor lists calcium pantothenate first, followed by sodium alginate, in a 425 mg complex, so by labeling logic its sodium alginate can’t exceed 50% (212.5 mg), an estimated 4.7x less than Refluxter. Another competitor lists sodium alginate first in a 338 mg complex; we estimate its sodium alginate at 240 to 300 mg per serving, an estimated 3.3x to 4.1x less. These are label-based estimates for the specific competitor products we compared, current as of our review. Refluxter also contains no sugars or artificial sweeteners, and instead of a gel you have to measure, it’s a simple capsule. If you’d like to see the full label, explore Refluxter.

Lifestyle Changes That Help

Lifestyle adjustments are a powerful lever for controlling GERD. Some of the most effective changes include:

• Lose excess weight and maintain a healthy body composition.
• Avoid tight-fitting clothes around the waist.
• Stop smoking (we know it’s easier said than done).
• Don’t lie down or stoop shortly after eating.
• Raise the head of your bed 6 to 8 inches so you sleep on an incline. Most nighttime acid refluxes early in the night when you’re lying flat without gravity’s help.

Your primary care physician or gastroenterologist can tailor a plan to your history and needs, so it’s always worth discussing additional measures with them.

Summary

Let’s recap the big takeaways about Barrett’s esophagus:

• Barrett’s is a precancerous change driven by reflux. Chronic acid exposure transforms the esophageal lining into intestinal-type cells.
• The cancer risk is real but small. Only about 0.1% to 0.3% of patients progress to esophageal cancer each year, and guideline-directed surveillance catches early changes when they are most treatable.
• Management is guideline-directed. Daily PPI therapy when appropriate, endoscopic surveillance on risk-stratified intervals, and endoscopic eradication therapy when dysplasia is confirmed.
• Alginate rafts have clinical evidence for reducing reflux. They form a floating barrier; alginates are more effective than placebo or antacids for relieving GERD symptoms (Leiman et al.) and reduce post-meal acid reflux episodes (Rohof et al.). A 2023 laboratory study and a small unpublished pilot have also explored alginate in Barrett’s-specific settings, but no clinical study has established that alginate treats Barrett’s or prevents its progression.
• Stay on your prescribed treatment. An alginate supplement is not a substitute for PPI therapy, surveillance, or any other treatment your gastroenterologist recommends.

At Nutritist, we believe science should guide what we put in our bodies, which is why Refluxter was formulated around the published alginate research. If you have Barrett’s esophagus, work with your physician, keep up your prescribed treatment and surveillance schedule, and ask whether an alginate supplement makes sense alongside your plan.

Disclaimer: This article is not intended to provide medical advice. It is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment, nor does it constitute a patient-physician relationship. The statements in this article have not been evaluated by the Food and Drug Administration. Refluxter is not intended to diagnose, treat, cure, or prevent any disease, including Barrett’s esophagus. Please consult your physician for medical advice.

Frequently Asked Questions

Is Barrett’s esophagus cancer?

No. Barrett’s esophagus is a precancerous change in the esophageal lining. It raises the risk of esophageal cancer, but only about 0.1% to 0.3% of patients progress to cancer each year, and surveillance helps catch any changes early.

Can Barrett’s esophagus be reversed?

The cellular changes generally don’t reverse on their own. Endoscopic eradication therapy can remove dysplastic tissue when dysplasia is present, and controlling reflux with guideline-directed therapy is central to management. Discuss your options with your gastroenterologist.

Does acid reflux always lead to Barrett’s esophagus?

No. Only about 5% to 13% of people with GERD develop Barrett’s, and longstanding reflux (over a decade) raises the odds. Controlling GERD early reduces the risk of developing it.

How is Barrett’s esophagus diagnosed?

Through an upper endoscopy, during which a doctor inspects the lower esophagus and takes a tissue biopsy. A pathologist then examines the sample for dysplasia (precancerous cells).

What does research on sodium alginate mean for people with Barrett’s esophagus?

Alginate therapy has been studied for controlling gastroesophageal reflux, not for treating Barrett’s esophagus itself. Because reflux management is an important part of care for many people with Barrett’s, researchers have also investigated whether alginate may help limit exposure of the esophagus to refluxed gastric contents. However, clinical studies have not established that alginate reverses Barrett’s esophagus or reduces the risk of progression to dysplasia or cancer. Follow your gastroenterologist’s treatment and surveillance plan.

How much sodium alginate does Refluxter contain?

Refluxter delivers 1,000+ mg of sodium alginate per serving as the first-listed ingredient in its 1,470 mg alginate complex, in a capsule with no sugars or artificial sweeteners. See the formulation section above for how that compares, by label-based estimate, with two competitor gels.

References

Bor, Serhat, et al. “Alginates: From the Ocean to Gastroesophageal Reflux Disease Treatment.” Turkish Journal of Gastroenterology, vol. 30, suppl. 2, 2019, pp. S109-S136.

Leiman, David A., et al. “Alginate Therapy Is Effective Treatment for Gastroesophageal Reflux Disease Symptoms: A Systematic Review and Meta-Analysis.” Diseases of the Esophagus, vol. 30, no. 5, 2017, pp. 1-9.

Rohof, Wout O., et al. “An Alginate-Antacid Formulation Localizes to the Acid Pocket to Reduce Acid Reflux in Patients With Gastroesophageal Reflux Disease.” Clinical Gastroenterology and Hepatology, vol. 11, no. 12, 2013, pp. 1585-1591.

Samuels, Tina L., et al. “Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.” International Journal of Molecular Sciences, vol. 24, no. 9, 2023, article 7932.

Medical University of South Carolina. “The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett’s Esophagus.” ClinicalTrials.gov, identifier NCT03193216, results posted 2023.

Shaheen, Nicholas J., et al. “Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline.” American Journal of Gastroenterology, vol. 117, no. 4, 2022, pp. 559-587.

American Gastroenterological Association. “AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia.” Gastroenterology, vol. 166, no. 6, 2024.

American Gastroenterological Association. “AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus.” Gastroenterology, 2025.

National Institute of Diabetes and Digestive and Kidney Diseases. “Definition & Facts for GER & GERD.” NIDDK.